OUR PRODUCTS

250 mg film-coated tablets

(Ivosidenib)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)

Please visit the following link(s)

2.5 mg and 5 mg and 10 mg

(Perindopril arginine)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

5 mg /1.25 mg

(Perindopril arginine and indapamide)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

30 mg

(Gliclazide)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

15 mg/6.14 mg and 20 mg/8.19 mg

(Trifluridine and tipiracil hydrochloride)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

2.5 mg

(Indapamide)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

1.5 mg

(Indapamide)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

750 U/ml

(Pegaspargase)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

4.3 mg/ml

(Irinotecan)

To read the most recent version of the Summary of Product Characteristics (SmPC)

Please visit the following link:

29 mg

(Pixantrone)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

5 mg and 7.5 mg

(Ivabradine)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):

25 mg

(Agomelatine)

To read the most recent version of the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL).

Please visit the following link(s):